Selection of proton pump inhibitors for formulary inclusion: Making decisions based on appropriate criteria

Stephen W. Nissen, Keith M. Olsen

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations


To accurately assess any therapeutic class or specific agent for inclusion in the hospital formulary, a consistent evidence-based review process should be followed. Utilization of any therapeutic class, including the proton pump inhibitors, is more efficient if a single agent is used throughout the healthcare system. The lack of evidence supporting intravenous proton pump inhibitor therapy in stress-related mucosal damage and no comparative data in non-variceal upper gastrointestinal bleeding allows interchange of all agents more readily. Although many factors need consideration, the ideal proton pump inhibitor should be available orally and intravenously, and be prepared easily for administration to patients unable to swallow capsules or tablets. Using these criteria, the hospital system may be able to leverage the best possible cost for selection of a proton pump inhibitor for their formulary.

Original languageEnglish (US)
Pages (from-to)289-298
Number of pages10
JournalDisease Management and Health Outcomes
Issue number5
StatePublished - 2007


  • Esomeprazole, therapeutic use
  • Formularies
  • Intravenous
  • Lansoprazole, therapeutic use
  • Omeprazole, therapeutic use
  • Oral
  • Pantoprazole, therapeutic use
  • Proton pump inhibitors, therapeutic use
  • Rabeprazole, therapeutic use
  • Routes of administration

ASJC Scopus subject areas

  • Leadership and Management
  • Nursing(all)
  • Health Policy


Dive into the research topics of 'Selection of proton pump inhibitors for formulary inclusion: Making decisions based on appropriate criteria'. Together they form a unique fingerprint.

Cite this